Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Quitosanos no aleatorios

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20190116001
Publicado:
29/01/2019
Caducidad:
29/01/2020
Resumen:
Una universidad alemana ofrece un nuevo proceso para la preparación de polímeros de quitosano no aleatorios. Estos polímeros se caracterizan por un patrón definido de acetilación y una mayor biocompatibilidad. Las aplicaciones son numerosas, desde biomedicina y agricultura hasta cosmética e industria alimentaria. Los quitosanos con un bajo grado de acetilación y, por consiguiente, con una densidad relativamente alta de cargas positivas, son especialmente interesantes, por ejemplo en forma de nanopartículas, para la administración de fármacos, genes o vacunas. La universidad busca socios industriales con el fin de establecer acuerdos de licencia e implementar el proceso cuando se requieran propiedades antimicrobianas, de fortalecimiento de plantas y cicatrización de heridas.

Details

Tittle:
Non-random chitosans
Summary:
A German university offers a new process for the preparation of non-random chitosan polymers. These are characterized by a defined pattern of acetylation and increased biocompatibility. Applications are manifold, e.g. in biomedicine, agriculture, cosmetics and food industry. Industrial partners from these sectors are sought for license agreements.
Description:
Chitosans are a family of functional biopolymers, typically produced by partial de-N-acetylation of chitin, one of the most abundant biopolymers in the world. The unique polycationic nature of chitosans is at least partially responsible for the many bioactivities of chitosans, such as their antimicrobial, plant-strengthening and wound-healing activities, which make them extremely valuable compounds for applications in biomedicine, agriculture, cosmetics and in the food industry. These bioactivities are deeply influenced by the degree of acetylation of the chitosan used.

As an example, chitosans with a low degree of acetylation, and, as a consequence, with a relatively high density of positive charges, are particularly interesting, for example, in form of nanoparticles for drug, gene or vaccine delivery. However, the degradation of such chitosans in the human body is very slow or inexistent, as humans do not possess chitosanases, i.e. enzymes that cleave the glycosidic linkage between two adjacent GlcN (glucosamine) units. Thus, they are found to be hardly or even not approvable by the Food and Drug Administration (FDA) for medical purposes.

Humans do possess chitinases and lysozyme, i.e. enzymes that hydrolyse the chitosan polymer chain within a stretch of two or three adjacent GlcNAc (N-acetylglucosamine) residues, respectively. But as conventional chitosans are characterised by random patterns of acetylation, such acetylated stretches which could serve as cleavage sites are rare.

The present invention of a German university relates to a process for the preparation of a non-random chitosan polymer. It is derived by using a deacetylase enzyme in the presence of acetate ions under conditions that allow acetylation of the poly-D-glucosamine by said chitin deacetylase. Thus a chitosan polymer is obtained that presents a defined, e.g. blockwise or more regular pattern of acetylation so that e.g. even chitosans with low degree of acetylation are more easily degraded by human enzymes. These are just some of the advantages that can be created compared to chitosans with undefined acetylation patterns.

Industrial partners are sought to implement the process wherever the antimicrobial, plant-strengthening and wound-healing features are required. This could be in biomedicine, agriculture, cosmetics and food industry. License agreements are targeted.
Advantages and Innovations:
Conventional chitosans are characterised by random patterns of acetylation. The innovation of this invention lies in the defined pattern of acetylation. This is a new process that leads to increased biocompatibility and therefore enables a broad range of applications.

Further advantages are that it is easily degradable in human tissues and thus likely better approvable by FDA (food and drug administration) or other authorities.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
International patent applied

Partner sought

Type and Role of Partner Sought:
The university offers license agreements for the invention to interested companies. Partners could be active in biomedicine, agriculture, cosmetics and in the food industry. They should implement this technology in their processes.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001024 Biomateriales médicos
06006004 Biopolímeros
06004 Micro y nanotecnología relacionada con las ciencias biológicas
08002002 Microbiología / toxicología / control de calidad de alimentos